Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
3950results about "Fused cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Humanized anti-TGF-beta antibodies
Owner:GENENTECH INC
Soybean cultivar SN79525
InactiveUS6967263B2Improve nutritional qualitySugar derivativesOther foreign material introduction processesCultivar
A novel soybean cultivar, designated SN79525, is disclosed. The invention relates to the seeds of soybean cultivar SN79525, to the plants of soybean SN79525 and to methods for producing a soybean plant produced by crossing the cultivar SN79525 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar SN79525 with another soybean cultivar.
Owner:MONSANTO TECH LLC
Soybean cultivar 0037357
A soybean cultivar, designated 0037357, is disclosed. The invention relates to the seeds of soybean cultivar 0037357, to the plants of soybean 0037357 and to methods for producing a soybean plant produced by crossing the cultivar 0037357 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar 0037357 with another soybean cultivar.
Owner:MONSANTO TECH LLC
Soybean variety SE90346
InactiveUS6958436B2Improve nutritional qualitySugar derivativesOther foreign material introduction processesCultivar
A soybean cultivar, designated SE90346, is disclosed. The invention relates to the seeds of soybean cultivar SE90346, to the plants of soybean SE90346 and to methods for producing a soybean plant produced by crossing the cultivar SE90346 with itself or another soybean variety. The invention further relates to hybrid soybean seeds and plants produced by crossing the cultivar SE90346 with another soybean cultivar.
Owner:MONSANTO TECH LLC
Synthetic antibody phage libraries
InactiveUS20050079574A1High-quality target binding characteristicGenerate efficientlyAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsHeterologousIntravenous gammaglobulin
The invention provides immunoglobulin polypeptides comprising variant amino acids in CDRs of antibody variable domains. In one embodiment, the polypeptide is a variable domain of a monobody and has a variant CDRH3 region. These polypeptides provide a source of great sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.
Owner:GENENTECH INC
Simultaneous stimulation and concentration of cells
InactiveUS6867041B2Maximizes stimulationCulture processArtificial cell constructsDrug discoveryCells signal
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and / or stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.
Owner:LIFE TECH CORP
Binding polypeptides with restricted diversity sequences
InactiveUS20070237764A1Small sizeHigh-quality target binding characteristicFermentationVector-based foreign material introductionHeterologousAntigen binding
The invention provides variant CDRs comprising highly restricted amino acid sequence diversity. These polypeptides provide a flexible and simple source of sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.
Owner:GENENTECH INC
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
ActiveUS20070160598A1Raise the possibilitySmall sizeAnimal cellsSugar derivativesAntibody hypervariable regionBioinformatics
The invention provides variant hypervariable regions comprising selected amino acid sequence diversity. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.
Owner:GENENTECH INC
Phage antibodies
Peripheral blood leucocytes incubated with a semi-synthetic phage antibody library and fluorochrome-labeled CD3 and CD20 antibodies were used to isolate human single chain Fv antibodies specific for subsets of blood leucocytes by flow cytometry. Isolated phage antibodies showed exclusive binding to the subpopulation used for selection or displayed additional binding to a restricted population of other cells in the mixture. At least two phage antibodies appeared to display hithereto unknown staining patterns of B lineage cells. This approach provides a subtractive procedure to rapidly obtain human antibodies against known and novel surface antigens in their native configuration, expressed on phenotypically defined subpopulations of cells. Importantly, this approach does not depend on immunization procedures or the necessity to repeatedly construct phage antibody libraries.
Owner:JANSSEN VACCINES & PREVENTION BV
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
Owner:KYOWA HAKKO KIRIN CO LTD
Method for making multispecific antibodies having heteromultimeric and common components
InactiveUS7183076B2Increased formationIncrease productionAnimal cellsAntibody mimetics/scaffoldsSpecific immunityBispecific antibody
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method futher involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and / or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
Owner:GENENTECH INC
Super humanized antibodies
InactiveUS6881557B2Antibody mimetics/scaffoldsAnalogue computers for chemical processesHuman sequenceHumanized antibody
Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences. Top ranking human sequences are selected to provide the framework sequences for constructing a chimeric antibody that functionally replaces human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed.
Owner:ARROWSMITH TECH
PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
ActiveUS20120039906A1Reduced activityStrong cytotoxicityAntibacterial agentsAnimal cellsPD-L1Antibody
Owner:INST JEAN PAOLI & IRENE CALMETTES +2
CD19-specific chimeric T cell receptor
InactiveUS7446179B2Peptide/protein ingredientsAntibody mimetics/scaffoldsIntracellular signallingTransmembrane domain
The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:ζ receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ζ are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2. The present invention further relates to a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
Owner:CITY OF HOPE
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ActiveUS7217797B2Function increaseExtended half-lifeAnimal cellsSugar derivativesAntiendomysial antibodiesBiochemistry
Owner:ABBOTT BIOTHERAPEUTICS CORP
CE7-specific redirected immune cells
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc:ζ receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge —CH2—CH3 region of a human IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.
Owner:CITY OF HOPE
Cysteine engineered antibodies and conjugates
ActiveUS20070092940A1Sugar derivativesImmunoglobulins against cell receptors/antigens/surface-determinantsCross-linkCysteine thiolate
Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
Owner:GENENTECH INC
Multivalent antibody constructs
InactiveUS7129330B1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsVariable domainPlasmid
The present invention relates to multivalent Fvantibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fvantibody construct and a method of producing the Fvantibody constructs as well as their use.
Owner:DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS
Plants and seeds of corn variety I285291
According to the invention, there is provided seed and plants of the corn variety designated I285291. The invention thus relates to the plants, seeds and tissue cultures of the variety I285291, and to methods for producing a corn plant produced by crossing a corn plant of variety I285291 with itself or with another corn plant, such as a plant of another variety. The invention further relates to corn seeds and plants produced by crossing plants of variety I285291 with plants of another variety, such as another inbred line. The invention further relates to the inbred and hybrid genetic complements of plants of variety I285291.
Owner:MONSANTO TECH LLC
Method for making heteromultimeric polypeptides
InactiveUS20070014794A1Increase productionAntibacterial agentsPeptide/protein ingredientsCrystallographyAmino acid side chain
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.
Owner:GENENTECH INC
Insect-resistant transgenic plants
The invention provides transgenic plants and transformed host cells which express modified cry 3B genes with enhanced toxicity to Coleopteran insects. Also disclosed are methods of making and using these transgenic plants, methods of making recombinant host cells expressing these delta -endotoxins, and methods of killing insects such as Colorado potato beetle (Leptinotarsa decemlineata), southern corn rootworm (Diabrotica undecimpunctata howardi Barber) and western corn rootworm (Diabrotica virgifera virgifera LeConte.
Owner:MONSANTO CO (MONSANTO CY)
Synthetic genes encoding cry1ac
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions containing a synthetic nucleotide sequence encoding a Cry1Ac protein are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided, wherein the nucleotide sequences are set forth in SEQ ID NO:1, 2, 3, 4, 5 or 6, as well as variants and fragments thereof.
Owner:ATHENIX
Fc fusion proteins of human erythropoietin with increased biological activities
InactiveUS6900292B2Improve biological activityExtended serumPeptide/protein ingredientsAntibody mimetics/scaffoldsSide effectHalf-life
Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Owner:LONGBIO PHARM (SUZHOU) CO LTD
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
InactiveUS20070148164A1Increase free energyReduced binding affinityAnimal cellsSugar derivativesFc bindingNeonatal Fc receptor
The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
Owner:BIOGEN MA INC
Monoclonal antibodies detection methods for enzymes that confer resistance to 2,4-dichlorophenoxyacetic acid in plants
ActiveUS8460891B2Animal cellsImmunoglobulins against cytokines/lymphokines/interferonsMonoclonal antibodyDioxygenase
Owner:CORTEVA AGRISCIENCE LLC
Anti-RSV antibodies
InactiveUS6818216B2Reduce dosing frequencyReduce dosageAnimal cellsSugar derivativesSerum igeAntibody fragments
Owner:MEDIMMUNE LLC
Antibody specificity transfer using minimal essential binding determinants
The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
Owner:HUMANIGEN INC
Production of proteins by cell culture
InactiveUS6413746B1High protein yieldReduce cell viabilityImmunoglobulins against blood group antigensPeptide/protein ingredients3D cell cultureBiochemistry
Methods for obtaining a protein by culture of hybridoma cells, wherein said protein is an immunoglobulin, are disclosed. The methods involve culturing animal hybridoma cells in continuous presence of an alkanoic acid or salt thereof, which enhances protein production, wherein said alkanoic acid or salt thereof is present at 2 concentration range of 0.1 mM to 200 mM.
Owner:LONZA LTD
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
InactiveUS6113898AShrink tumorInhibit tumor growthPeptide/protein ingredientsAntipyreticDiseaseOrgan transplant rejection
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and / or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Owner:BIOGEN INC
Monoclonal antibodies and detection methods for phosphinothricin-N-acetyl-transferase enzyme
ActiveUS9371394B2Immunoglobulins against bacteriaBiological material analysisN-acetyltransferaseAcetyltransferase
Owner:CORTEVA AGRISCIENCE LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com